Detecting biological heterogeneity patterns in ADNI amnestic mild cognitive impairment based on volumetric MRI
There is substantial biological heterogeneity among older adults with amnestic mild cognitive impairment (aMCI). We hypothesized that this heterogeneity can be detected solely based on volumetric MRI measures, which potentially have clinical implications and can improve our ability to predict clinical outcomes. We used latent class analysis (LCA) to identify subgroups among persons with aMCI (n = 696) enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), based on baseline volumetric MRI measures. We used volumetric measures of 10 different brain regions. The subgroups were validated with respect to demographics, cognitive performance, and other AD biomarkers. The subgroups were compared with each other and with normal and Alzheimer’s disease (AD) groups with respect to baseline cognitive function and longitudinal rate of conversion. Four aMCI subgroups emerged with distinct MRI patterns: The first subgroup (n = 404), most similar to normal controls in volumetric characteristics and cognitive function, had the lowest incidence of AD. The second subgroup (n = 230) had the most similar MRI profile to early AD, along with poor performance in memory and executive function domains. The third subgroup (n = 36) had the highest global atrophy, very small hippocampus and worst overall cognitive performance. The fourth subgroup (n = 26) had the least amount of atrophy, however still had poor cognitive function specifically in in the executive function domain. Individuals with aMCI who were clinically categorized within one group other showed substantial heterogeneity based on MRI volumetric measures.
KeywordsLatent class analysis Volumetric MRI Cognitive function Amnestic MCI Alzheimer’s disease
Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at https://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Data collection and sharing for ADNI project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.
Authors of this study were supported in part by National Institutes of Health grants NIA 2 P01 AG03949, NIA 1R01AG039409–01, NIA R03 AG045474, NIH K01AG054700, the Leonard and Sylvia Marx Foundation, and the Czap Foundation.
Compliance with ethical standards
Conflict of interest
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- Armitage, P., Berry, G., Matthews, J. N. S. (2008). Statistical methods in medical research. John Wiley & Sons.Google Scholar
- Ball, K., Berch, D. B., Helmers, K. F., Jobe, J. B., Leveck, M. D., Marsiske, M., Morris, J. N., Rebok, G. W., Smith, D. M., Tennstedt, S. L., Unverzagt, F. W., Willis, S. L., & ACTIVE Study Group. (2002). Effects of cognitive training interventions with older adults: A randomized controlled trial. JAMA., 288, 2271–2281.CrossRefGoogle Scholar
- Bondi, M. W., Edmonds, E. C., Jak, A. J., Clark, L. R., Delano-Wood, L., McDonald, C. R., Nation, D. A., Libon, D. J., Au, R., Galasko, D., & Salmon, D. P. (2014). Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. Journal of Alzheimer's Disease, 42, 275–289.CrossRefGoogle Scholar
- DeCarli, C., Maillard, P., Fletcher, E. (2013). Four tissue segmentation in ADNI II. Alzheimer’s Disease Neuroimaging Initiative. Department of Neurology and Center for Neuroscience, University of California at Davis.Google Scholar
- Edmonds, E. C., Delano-Wood, L., Clark, L. R., Jak, A. J., Nation, D. A., McDonald, C. R., Libon, D. J., Au, R., Galasko, D., Salmon, D. P., Bondi, M. W., & Alzheimer's Disease Neuroimaging Initiative. (2015). Susceptibility of the conventional criteria for mild cognitive impairment to false-positive diagnostic errors. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 11, 415–424.CrossRefGoogle Scholar
- Eppig, J. S., Edmonds, E. C., Campbell, L., Sanderson-Cimino, M., Delano-Wood, L., Bondi, M. W., & for the Alzheimer’s Disease Neuroimaging Initiative. (2017). Statistically derived subtypes and associations with cerebrospinal fluid and genetic biomarkers in mild cognitive impairment: A latent profile analysis. Journal of the International Neuropsychological Society, 23, 564–576.CrossRefGoogle Scholar
- Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., Montillo, A., Makris, N., Rosen, B., & Dale, A. M. (2002). Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron., 33, 341–355.CrossRefGoogle Scholar
- Gibbons, L. E., Carle, A. C., Mackin, R. S., Harvey, D., Mukherjee, S., Insel, P., et al. (2012). A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging and Behavior, 6, 517–527.CrossRefGoogle Scholar
- Landau, S. M., Harvey, D., Madison, C. M., Koeppe, R. A., Reiman, E. M., Foster, N. L., Weiner, M. W., Jagust, W. J., & Alzheimer’s Disease Neuroimaging Initiative. (2011). Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiology of Aging, 32, 1207–1218.CrossRefGoogle Scholar
- Mohs, R. (1994). Administration and scoring manual for the Alzheimer’s disease assessment scale, 1994 revised edition. New York: The Mount Sinai School of Medicine.Google Scholar
- Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005). Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 1, 55–66.CrossRefGoogle Scholar
- Partington, J. E., Leiter, R. G. (1949). Partington's pathways test. Psychological Service Center Journal.Google Scholar
- Rey, A. (1958). L'examen clinique en psychologie.Google Scholar
- Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., & Kivipelto, M. (2014). Clinical trials and late-stage drug development for Alzheimer's disease: An appraisal from 1984 to 2014. Journal of Internal Medicine, 275, 251–283.CrossRefGoogle Scholar
- Schwarz, C., Fletcher, E., DeCarli, C., Carmichael, O. (2009). Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. International conference on information processing in medical imaging: Springer; p. 239–51.Google Scholar
- Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M. Y., Trojanowski, J. Q., & Alzheimer's Disease Neuroimaging Initiative. (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology, 65, 403–413.CrossRefGoogle Scholar
- Wechsler, D. (2014). Wechsler adult intelligence scale–fourth edition (WAIS–IV). San Antonio: Psychological Corporation.Google Scholar
- Willis, S. L., Tennstedt, S. L., Marsiske, M., Ball, K., Elias, J., Koepke, K. M., Morris, J. N., Rebok, G. W., Unverzagt, F. W., Stoddard, A. M., Wright, E., & ACTIVE Study Group. (2006). Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA., 296, 2805–2814.CrossRefGoogle Scholar
- Zammit, A. R., Muniz-Terrera, G., Katz, M. J., Hall, C. B., Ezzati, A., Bennett, D. A., et al. (2018a). Subtypes based on neuropsychological performance predict incident dementia: Findings from the rush memory and aging project. Journal of Alzheimer's Disease, 1–11.Google Scholar
- Zammit, A. R., Hall, C. B., Katz, M. J., Muniz-Terrera, G., Ezzati, A., Bennett D. A., et al. (2018b). Class-specific incidence of all-cause dementia and Alzheimer’s disease: A latent class approach. Journal of Alzheimer's Disease, 1–11.Google Scholar
- Zammit, A. R., Hall, C. B., Katz, M. J., Terrera, G. M., & Lipton, R. B. (2018c). Process of identifying A clinical model of latent neuropsychological profiles in community-dwelling older adults. Alzheimer's & Dementia: The Journal of the Alzheimer's Association., 14, P1298–P12P9.CrossRefGoogle Scholar
- Zammit, A. R., Hall, C. B., Lipton, R. B., Katz, M. J., & Muniz-Terrera, G. (2018d). Identification of heterogeneous cognitive subgroups in community-dwelling older adults: A latent class analysis of the Einstein aging study. Journal of the International Neuropsychological Society, 24, 511–523.CrossRefGoogle Scholar